Journal article icon

Journal article

A drug repurposing approach reveals targetable epigenetic pathways in Plasmodium vivax hypnozoites

Abstract:
Radical cure of Plasmodium vivax malaria must include elimination of quiescent ‘hypnozoite’ forms in the liver; however, the only FDA-approved treatments are contraindicated in many vulnerable populations. To identify new drugs and drug targets for hypnozoites, we screened the Repurposing, Focused Rescue, and Accelerated Medchem (ReFRAME) library and a collection of epigenetic inhibitors against P. vivax liver stages. From both libraries, we identified inhibitors targeting epigenetics pathways as selectively active against P. vivax and P. cynomolgi hypnozoites. These include DNA methyltransferase inhibitors as well as several inhibitors targeting histone post-translational modifications. Immunofluorescence staining of Plasmodium liver forms showed strong nuclear 5-methylcystosine signal, indicating liver stage parasite DNA is methylated. Using bisulfite sequencing, we mapped genomic DNA methylation in sporozoites, revealing DNA methylation signals in most coding genes. We also demonstrated that methylation level in proximal promoter regions as well as in the first exon of the genes may affect, at least partially, gene expression in P. vivax. The importance of selective inhibitors targeting epigenetic features on hypnozoites was validated using MMV019721, an acetyl-CoA synthetase inhibitor that affects histone acetylation and was previously reported as active against P. falciparum blood stages. In summary, our data indicate that several epigenetic mechanisms are likely modulating hypnozoite formation or persistence and provide an avenue for the discovery and development of improved radical cure antimalarials.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.7554/elife.98221

Authors

More by this author
Role:
Author
ORCID:
0000-0002-9560-5656
More by this author
Role:
Author
ORCID:
0000-0002-3337-6528
More by this author
Role:
Author
ORCID:
0000-0002-7945-961X
More by this author
Role:
Author
ORCID:
0000-0003-0665-7954


More from this funder
Funder identifier:
https://ror.org/01cwqze88
More from this funder
Funder identifier:
https://ror.org/03nawhv43
More from this funder
Funder identifier:
https://ror.org/00p9jf779
More from this funder
Funder identifier:
https://ror.org/0456r8d26


Publisher:
eLife Sciences Publications
Journal:
eLife More from this journal
Volume:
13
Article number:
RP98221
Publication date:
2025-09-30
DOI:
EISSN:
2050084X
ISSN:
2050084X


Language:
English
Keywords:
Pubs id:
2298378
Local pid:
pubs:2298378
Source identifiers:
3331662
Deposit date:
2025-10-01
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP